SureTrader Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, TPX, Peacefulwendy, The Promised Land, BioNewton, $Pistol Pete$
Search This Board:
Last Post: 7/1/2016 6:08:46 PM - Followers: 594 - Board type: Free - Posts Today: 39

Welcome to PharmaCyte BioTech
All Video About PharmaCyte Biotech heads into the final preparations for its Phase 2b clinical trial in advanced pancreatic cancer, the company hosted a medical and scientific discussion of our therapy for advanced pancreatic cancer among top oncologist investigators who have expressed interest in PharmaCyte’s technology and participation in the Phase 2b clinical trial. Below you will find the 5 presentations that were delivered to those invited oncologists. After Dr. Manuel Hidalgo, a member of PharmaCyte's medical and scientific advisory board, completed his presentation of the design of the upcoming Phase 2b clinical trial, an hour-long discussion took place between those invited oncologists and those representing PharmaCyte Biotech; Dr. Matthias Löhr, Dr. Manuel Hidalgo, Prof. Dr. Walter H. Günzburg, and Dr. Brian Salmons.



$PMCB Enjoy Corporate Video





$PMCB Enjoy Discovery Channel Video






$PMCB Enjoy Another Great Video YouTube TGen Leads the Way in Early Detection of Cancer. Dr. Von Hoff will lead $PMCB into FDA Fast Track Approval







FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe

Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.


Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development


Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).

Dr. Manuel Hidalgo, Scientific Advisory Board:

Manual Hidalgo is the Vice Director of Translational Research, Clinical Research Program Director and Head of Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) and Director at the Centro Integral Oncologico Clara Campal (CIOCC). In addition he is a professor of Oncology at the University CEU San Pablo. Dr. Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialized in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programs. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the Pancreatic Cancer Research Team (PCRT) - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. - See more at:



Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report


•The Board Monitor and The Board Assistants herewith, are not licensed brokers and
assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.

•We do NOT recommend that anyone buy or sell any securities posted herewith.
Any trade entered into risks the possibility of losing the funds invested.
•There are no guarantees when buying or selling any security.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PMCB News: PharmaCyte Biotech CEO Interviewed by Small Cap Nation 06/28/2016 12:31:59 PM
PMCB News: PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting 06/23/2016 09:20:00 AM
PMCB News: PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference 06/20/2016 09:00:00 AM
PMCB News: PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention 06/07/2016 09:20:00 AM
PMCB News: PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology 06/03/2016 09:20:00 AM
#49820  Sticky Note $PMCB Functional cure diabetes should finally become rea $Pistol Pete$ 07/01/16 05:55:52 PM
#49713  Sticky Note needs some fast action/ Looking for a Comeback mick 06/28/16 01:09:36 AM
#49622  Sticky Note PharmaCyte Biotech Releases Medical and Scientific Discussion from Peacefulwendy 06/23/16 10:12:56 AM
#49249  Sticky Note PMCB - Clinical Trial Costs - Not as BioNewton 06/03/16 09:30:47 PM
#48147  Sticky Note PMCB PharmaCyte Biotech Clears Major Milestone on Path TPX 05/05/16 09:40:56 AM
#49823   Yep ;-) Go $PMCB $Pistol Pete$ 07/01/16 06:25:55 PM
#49822   Great post Pete. The Diabetes Consortium and BioNewton 07/01/16 06:08:46 PM
#49821   Yeah, probably. So what? Some of BioNewton 07/01/16 05:56:29 PM
#49820   $PMCB Functional cure diabetes should finally become rea $Pistol Pete$ 07/01/16 05:55:52 PM
#49819   Agree! Undersold not oversold. Much more selling to frosr6 07/01/16 05:42:54 PM
#49818   Happy 4th of July those of you in BioNewton 07/01/16 05:38:03 PM
#49817   Don't you mean over sold? saladan2 07/01/16 04:56:06 PM
#49816   Agreed Go $PMCB $Pistol Pete$ 07/01/16 03:21:31 PM
#49815   See you at the finish line efood_dude 07/01/16 02:48:11 PM
#49814   $PMCB 15' Chart $Pistol Pete$ 07/01/16 02:43:58 PM
#49813   $PMCB PharmaCyte’s Innovative Platform Now Set to Target mick 07/01/16 02:38:33 PM
#49812   Food and Drug Administration and the Drug Enforcement mick 07/01/16 02:37:53 PM
#49811 mick 07/01/16 02:37:29 PM
#49810   his one could be your best shot my mick 07/01/16 02:36:31 PM
#49809   PharmaCyte Biotech to Present Cancer and Diabetes Therapies mick 07/01/16 02:35:50 PM
#49808   PharmaCyte Biotech to Present Clinical Trial at Marcum mick 07/01/16 02:35:32 PM
#49807 mick 07/01/16 02:35:13 PM
#49806   PharmaCyte Biotech CEO Interviewed by Small Cap Nation mick 07/01/16 02:34:50 PM
#49805   pmcb is way undersold/ 'PharmaCyte Biotech Inc. (PMCB)' mick 07/01/16 02:33:43 PM
#49804   Nice move today Go $PMCB $Pistol Pete$ 07/01/16 02:30:41 PM
#49803   some greenery/ Pharmacyte Biotech, (PMCB) mick 07/01/16 01:47:23 PM
#49802   Con artists make money by taking others not frosr6 07/01/16 01:22:26 PM
#49800   Efood- I look forward to the day I Brian903 07/01/16 01:02:59 PM
#49799   Good afternoon to you! I was thinking about Brian903 07/01/16 01:00:36 PM
#49798   $PMCB Daily Chart $Pistol Pete$ 07/01/16 12:35:44 PM
#49797   Because 13 d shows 5% owners. He does mind1 07/01/16 11:52:10 AM
#49796   I love this company and the huge potential rcstock 07/01/16 11:48:12 AM
#49795   You can email and contact below Investor Relations: PharmaCyte Biotech, $Pistol Pete$ 07/01/16 11:46:11 AM
#49794   I don't see it on 13d 1plus1 07/01/16 11:42:02 AM
#49793   They do not have too, they get it mind1 07/01/16 11:29:45 AM
#49792   What makes you think they are not? saladan2 07/01/16 11:24:48 AM
#49791   I'm with you on that. Patience is the saladan2 07/01/16 11:20:25 AM
#49790   You can email Ken Waqgoner for that information. BioNewton 07/01/16 11:18:30 AM
#49789   QUESTION??? Why would'nt the ceo or insider buy 1plus1 07/01/16 10:52:14 AM
#49788   Should this schedule hold, and I have every efood_dude 07/01/16 10:14:19 AM
#49787   Pancreatic cancer human trial to begin 4Q16, ascites/solid rudygerner 07/01/16 09:40:39 AM
#49786   Just heard Apple is thinking about taking over saladan2 07/01/16 09:11:58 AM
#49785   Morning Brian The Promised Land 07/01/16 06:15:31 AM
#49783   How's everything in England? Brian903 06/30/16 07:14:48 PM
#49782   :oD Go PMCB!!!! The Promised Land 06/30/16 05:28:38 PM
#49781   Prove it. Quote: "If you did your research you'd frosr6 06/30/16 02:42:12 PM
#49780   The MM's are forcing me to buy more. Mens et Manus 06/30/16 01:07:37 PM
#49779   Do not forget new trademark could be approved Brian903 06/30/16 12:36:44 PM
#49778   Price, at this time not too important. saladan2 06/30/16 12:14:06 PM
#49777   God forbid it should hold .06! Uboat 06/30/16 11:08:51 AM
#49776   If you did your research you'd see you saladan2 06/30/16 10:13:58 AM
#49775   No problem. Not sure who the Gangsta BioNewton 06/30/16 10:11:17 AM
#49774   Thanks Bio, for that Wall Street Gangsta article. saladan2 06/30/16 10:08:31 AM
#49772   Ken Waggoner has only been here for just BioNewton 06/30/16 08:55:33 AM
#49771   As pmcb reaches their 3rd yr of postponing frosr6 06/30/16 08:10:40 AM